Compare Novavax Inc (NVAX) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Zoom Video Communications, Inc. — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while Zoom Video Communications, Inc. trades at $97.71 (market cap $27.62B). The key difference: Zoom Video Communications, Inc. is far larger — about 15.2× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Zoom Video Communications, Inc. for 92 Days on average.
| NVAX | ZM | |
|---|---|---|
Market Cap | $1.82B | $27.62B |
Volume | 6,198,505 | 3,913,188 |
Sector | Health | Technology |
52-Week High | $12.56 | $111.88 |
52-Week Low | $6.22 | $72.72 |
Typical Hold Time | 59 Days | 92 Days |
Enterprise Value | $1.39B | $20.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Zoom Communications (ZM) trades at $97.74, up 3.13% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a net income margin of 65.19% and ROE of 32.14%, though recent earnings were mixed with one miss and two beats. Revenue growth is steady, projected to reach $5.0B in 2026, and the company is actively investing in AI-driven revenue tools, as highlighted by recent product launches.
The outlook for ZM is positive, with a consensus price target of $118.08 offering ~21% upside, supported by analyst buy ratings. Key risks include reliance on international sales and competitive pressures in the communication software space. Cash flow trends show variability, with net cash flow negative in 2025 and 2026, requiring monitoring of capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
